Updated: Apr 17, 2009
Muscle contusion indicates a direct, blunt, compressive force to a muscle. Contusions are one of the most common sports-related injuries.1,2,3 The severity of contusions ranges from simple skin contusions to muscle and bone contusions to internal organ contusions.
Although all tissue and organ contusions can result from traumatic sports injury, this article focuses on muscle contusions. Contusions of internal organs and bone contusions are not discussed in this article (see the eMedicine articles Concussion, Sacroiliac Joint Injury, Femur Injuries and Fractures, and Hip Pointer).
For excellent patient education resources, visit eMedicine's Skin, Hair, and Nails Center and Eye and Vision Center. Also, see eMedicine's patient education articles Bruises and Black Eye.
Contusions and strain injuries comprise approximately 60-70% of all sports-related injuries. In addition, most contusion injuries go unreported and untreated. Documented muscle contusions account for one third of all sports injuries. The quadriceps and gastrocnemius muscle groups are most often involved (see Images 1-2).4,5,6
The international frequency of contusions is similar to that in the United States.
Skeletal muscle constitutes the largest tissue mass in the body, comprising up to 45% of the total body weight. Muscles that cross a single joint are located close to bone, are frequently responsible for postural maintenance, and are most susceptible to contusions. On the other hand, 2-joint muscles, such as the rectus femoris muscle, lie more superficial and are more susceptible to stretch-induced strain injury.
Contusions are caused by blunt trauma to the outer aspect of the muscle, resulting in tissue and cellular damage and bleeding deep within the muscle and between the muscle planes.1 The resultant tissue necrosis and hematoma lead to inflammation.8 Little is known about the role of the inflammatory process and its importance in the healing process. Clearly, too much inflammation is unfavorable, but too little may be just as devastating.
A bruise is caused by blood that has escaped from damaged capillaries into the interstitial tissues. Within a few hours after the injury, the presence of necrotic tissue and hematoma initiates an inflammatory reaction. Because inflammation initiates macrophage action with subsequent phagocytosis of necrotic debris and stimulation of capillary production, it is vital to the process of muscle regeneration. However, inflammation invariably causes edema that leads to anoxia and further cell death.
The extent of the inflammatory response is often considered excessive and detrimental to muscle regeneration. However, controversy exists regarding this theory, because some literature indicates a worsened long-term outcome in patients placed on anti-inflammatory medications. Controversy also surrounds cryotherapy, with some literature touting its benefits, whereas others question its utility.9,10,11
Symptoms of a contusion are often nonspecific, and the diagnosis is one of exclusion.
Often, the physical examination in a patient with a suspected contusion is most important to exclude other injuries and narrowing the differential diagnosis. In general, tenderness to palpation and pain with PROM and AROM are the hallmarks of the physical examination. Depending upon the size of the lesion, a hematoma may also be appreciated. A complete examination of the injured area and surrounding areas must be emphasized to identify other possible injuries.
Any blunt trauma with sufficient force to propel its energy into the muscle can cause a contusion. Contusions are often the result of sports-related injuries.
Femur Injuries and Fractures
Quadriceps Injury
Other conditions that may be considered in certain circumstances include the following:
One must also consider coining and cupping, which are cultural remedies employed by traditional Asian families.
Imaging studies in patients with contusions may be helpful to rule out other significant disease processes.
Related eMedicine topics:
Compartment Syndrome [in the Physical Medicine and Rehabilitation section]
Compartment Syndrome, Extremity [in the Emergency Medicine section]
Compartment Syndrome, Lower Extremity [in the Orthopedic Surgery section]
Compartment Syndrome, Upper Extremity [in the Orthopedic Surgery section]
Compartment Syndromes
In the acute phase following a muscle contusion, hematoma maturation, inflammation, necrosis of damaged myofibrils, and phagocytosis of the necrotic debris are main features. The goal of therapy is to minimize hemorrhage and inflammation and control pain. Limb immobilization with rest, ice, compression, and elevation (RICE) should be performed for the first 24 hours in patients with minor contusions and for 48 hours in patients with moderate or severe contusions.
The general recommendation is to avoid heat during the first 24-48 hours to avoid increasing the extent of hemorrhage and edema. Once the lesion has stabilized, heat may help break up the mass of blood and tissue; however, in the literature, this has been shown to be of limited benefit.
The use of crutches should be emphasized for patients with thigh contusions, as weight bearing following the thigh contusion injury may be extremely painful and may extend the damage. The knee joint should be flexed to pain tolerance in conjunction with the compression dressing. Compression gently increases tension, limiting the extent of the intramuscular hematoma. In addition, the position of flexion stretches the muscle, which increases tension and also facilitates drainage of the edematous fluid from the region.
The contusion generally stabilizes by 24-48 hours, and subsequent evaluation should dictate further treatment and prognosis. Reinjury is a significant factor in prolonging disability, and patients must be instructed to avoid retraumatizing the muscle.
In the first phase of rehabilitation of a contusion, an occupational therapist may become involved by educating the patient about proper crutch use and tailoring the patient's activities of daily living (ADL) to the immobilized limb.
The index of suspicion for compartment syndrome must be high until the hemorrhage, swelling, and pain have subsided (see Miscellaneous, Medical/Legal Pitfalls).
Surgical intervention should not be necessary in cases of contusions, unless the diagnosis of compartment syndrome is considered and confirmed.
If the diagnosis is in question or if myositis ossificans is confirmed by radiographs, orthopedic consultation can be obtained. Compartment syndrome is a surgical emergency, and an immediate consultation should be made if the diagnosis is confirmed.
Multiple therapies that have become commonplace in the treatment of contusions exist. However, most therapies have not been proven to provide any benefit, and some may be damaging to the healing tissue.
In a given situation, an injection of epinephrine (with lidocaine) may be considered in the acute phase of a contusion injury, along with ice and compression to help limit bleeding.
In the second phase of muscle healing, known as the recovery or regeneration phase, the main feature is proliferation of reserve satellite cells and endomysial fibroblasts, followed by active protein synthesis. The main goal of this treatment phase is restoration of mobility and ROM. Early mobilization of the joint and muscle has been shown to dramatically reduce recovery time and increase tensile strength of the muscle. Early pain-free PROM establishes normal tissue planes, maintains uninjured muscle fiber excursion, and pumps excessive detritus from the soft tissue.
The patient is ready to progress to the next level of therapy when ROM has been restored. Jackson and Feagin found that a patient is ready to move on to the next phase of treatment when 90° of knee flexion is achieved.4
Pain-free PROM of the knee with emphasis on flexion should be encouraged. Gentle isometric muscle exercises can be performed as tolerated. Weight bearing should be allowed as tolerated. Excessive passive stretching of a previously immobilized limb has been shown to produce myositis ossificans in animal models. This potential complication must be balanced against laboratory evidence showing that mobilization demonstrates faster healing times and increased vascularity of the affected tissue.
Individualized education and instruction to adjust the athlete to ADL and routines with the injured limb may be needed to prevent reinjury, and working in conjunction with physical therapy to promote healing is advised.
Reinjury is a significant factor in prolonging disability. A fine line exists between a sufficient amount of therapy and too much therapy. Pain tends to be an effective and adequate guide.
Injection of medications into the contused tissue during the recovery phase, and any phase, has not been shown to be beneficial and may in fact be damaging to the tissues; this is especially true of corticosteroids.
The third phase of muscle healing, known as maturation or remodeling, is characterized by a gradual recovery of the functional properties of the muscle, including the recovery of the tensile strength of its connective tissue component. The goal of this phase is to maintain the ROM while restoring full function to the muscle and joint. Progressive resistance exercises are encouraged until full strength and ROM are regained.
Emphasis should be placed on regaining full ROM and restoring strength. Remember that therapy that is too aggressive and too early can result in reinjury caused by muscle strain.
Reevaluation of the patient' s daily activities and increasing tolerance to normal use of the contused limb should be emphasized.
Maintain agility by participation in noncontact sports such as squash, tennis, badminton, and swimming.
The physician needs to make every effort to relieve pain as completely and expeditiously as possible. Distinguishing the intensity of the pain can be difficult, because it tends to be subjective; therefore, treatment and therapy should be individualized.
Objective parameters, such as tachycardia, are unreliable. Usually, minor trauma to the muscles is self-limited. An enormous selection of analgesics is available for use by the physician, but pharmacologic agents tend to fall into 2 general categories: nonnarcotic and narcotic analgesics. The physician also must consider the best route of delivery of the drug.
Corticosteroids should not be used; they are catabolic, and they inhibit the healing process. These steroids promote overall negative nitrogen balance and loss of muscle. However, these agents continue to be used clinically to treat muscle contusion injuries and are injected into the site of injury to relieve the pain and to expedite a player's return to active status. This inhibition of the inflammatory response may have a sparing effect on the local muscle tissue and, perhaps, on the athlete as a whole in the short term; however, corticosteroids seem to cause an unwanted atrophy of both injured and uninjured muscles.18,22,24
Anabolic steroids may be proven useful in the treatment of contusion injuries because of the effects they have on nitrogen and protein balance and on stimulation of cell synthesis; however, research currently is limited.18 Many sporting governing bodies also control the use of anabolic steroids in their athletes, making the use of these agents controversial.
Pain accompanying minor acute soft-tissue injuries may be relieved by a short course of nonnarcotic analgesics with acetaminophen.
Ordinarily, the most commonly ingested pain reliever. Also marketed in combination with other drugs to provide analgesia. Advantages include availability, cost, and relatively high safety profile. The onset of relief is usually within 20-30 min. Extended release preparations do not appear to offer major benefits (other than dosing convenience) and may increase the incidence of toxicity. For children, acetaminophen is available as drops (80 mg/0.8 mL), elixirs (160 mg/5 mL), tablets (80 mg, 160 mg, 325 mg), and suppositories (125 mg, 325 mg).
650-1000 mg PO q4h; not to exceed 4,000 mg/d PO
10-15 mg/kg/dose PO q4-6h
Rifampin can interact to reduce the analgesic effects of acetaminophen; conversely, barbiturates, carbamazepine, alcohol, hydantoins, zidovudine, and isoniazid may increase acetaminophen hepatotoxicity
Documented hypersensitivity; known G6PD
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Use with care in patients who are malnourished; hepatotoxicity can occur in those with chronic alcoholism following various dosage levels
Controversial data exist on NSAIDs. By suppressing the initial inflammatory reaction, the NSAID permits improved performance in early time periods but appears to suppress the stimulus that may be needed for cellular remodeling in longer time periods. NSAIDs also may increase the amount of bleeding within the tissue. Currently, there is a lack of compelling evidence for either argument.
Although acetaminophen is typically listed with NSAIDs, this agent lacks anti-inflammatory properties and is used for its antipyretic and analgesic effects.
A number of NSAIDs are available for use. NSAIDs share a common mechanism of action, inhibiting the production of pain-mediating prostaglandins. Generally, NSAIDs provide a comparable degree of pain and inflammatory relief, but they differ in dosing schedule.
The 5 categories of marketed NSAIDs are acetic acid derivatives, fenamates, oxicams, propionic acid derivatives, and related compounds. Numerous NSAIDs are obtainable over the counter (OTC). Choosing an NSAID to prescribe can be difficult because few data exist that compare these agents, and individual responses are inconsistent. With a lack of evidence that one NSAID proves to be clearly superior, base prescribing decisions on personal experience, safety profiles, cost, and convenience.
Rapidly absorbed; metabolism occurs in liver by demethylation, deacetylation, and glucuronide conjugation; inhibits prostaglandin synthesis.
25-50 mg PO bid/tid
75 mg SR PO bid; not to exceed 200 mg/d
1-2 mg/kg/d divided PO bid/qid; not to exceed 4 mg/kg/d or 150-200 mg/d
Coadministration with aspirin increases risk of inducing serious NSAID-related side effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently
Documented hypersensitivity; GI bleeding or renal insufficiency
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
Acute renal insufficiency, hyperkalemia, hyponatremia, interstitial nephritis, and renal papillary necrosis may occur; increases risk of acute renal failure in patients with preexisting renal disease or compromised renal perfusion; reversible leukopenia may occur, (discontinue if there is persistent leukopenia, granulocytopenia, or thrombocytopenia)
Has become the choice of parenteral pain medications dispensed in the ED. Frequently overlooked is the fact that this medication is an NSAID, carrying all its attendant risks, and it is almost 20 times the cost of morphine (and 140 times the cost of ibuprofen). Few data supporting its superiority over other analgesics exist.
10 mg PO q6h prn
15-30 mg IV/IM q6h prn, give IV dose over 15-30 sec; not to exceed 5 d of treatment
<16 years: 0.5 mg/kg/dose IV/IM q6h; not to exceed 30 mg q6h
>16 years: Administer as in adults
Administered concurrently with aspirin increases the risk of inducing serious NSAID-related side effects; probenecid may increase the concentrations and possibly the toxicity of NSAIDs; may prolong PT when administered concurrently with anticoagulants; closely monitor PT, and instruct patients to watch for signs and symptoms of bleeding; may increase the risk of methotrexate toxicity (eg, stomatitis, bone marrow suppression, nephrotoxicity); phenytoin levels may be increased when administered concurrently
Documented hypersensitivity; do not administer into CNS; do not administer to patients diagnosed with peptic ulcer disease, recent GI bleeding or perforation, and renal insufficiency or to those patients at high risk of bleeding
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
Acute renal insufficiency, hyperkalemia, hyponatremia, interstitial nephritis, and renal papillary necrosis may occur; increases the risk of acute renal failure in patients with preexisting renal disease or compromised renal perfusion; low WBC counts rarely occur and usually return to normal in ongoing therapy; discontinuation of the therapy may be necessary if persistent leukopenia, granulocytopenia, or thrombocytopenia occur
Perform ophthalmologic studies in patients who develop eye complaints during therapy; therapy should be discontinued if changes are noted; changes may include blurred or diminished vision, corneal deposits, retinal disturbances, scotomata, changes in color vision, and macular degeneration
This prevalently used NSAID, also available OTC, is a derivative of the propionic class of NSAIDs and is considered the safest of the NSAIDs. Available as tablets of 200 mg, 400 mg, 600 mg, and 800 mg. Pediatric dosage forms are available as both a tablet and oral suspension (20 mg/mL). Advise taking ibuprofen with food or milk, if possible. Prescribe with caution in children with flulike illnesses.
400-600 mg PO q6h
Alternative dosing: 800 mg PO q8h
30-50 mg/kg/d PO divided qid; not to exceed 2400 mg/d
Increased toxicity if used with oral hypoglycemic agents, phenytoin, and warfarin; interferes with ACE inhibitors and beta-blockers; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of loop diuretics when administered concurrently; PT may increase when administered concurrently with anticoagulants; closely monitor PT, and instruct patients to watch for signs and symptoms of bleeding; ibuprofen and other NSAIDs may increase serum phenytoin and lithium levels as well as risk of methotrexate toxicity
Documented hypersensitivity; because of potential cross-sensitivity to other NSAIDs, do not give these agents to patients in whom aspirin, iodides, or other NSAIDs induce hypersensitivity; do not administer to patients diagnosed with peptic ulcer disease, recent GI bleeding or perforation, and renal insufficiency or to those patients at high risk of bleeding
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
Caution in patients with congestive heart failure, hypertension, and decreased renal and hepatic function
Patients complaining of inadequate pain relief from NSAIDs may benefit from short-term supplementation with an opioid compound. A wide array of products is available.
Orally (PO), hydrocodone (eg, Lortab, Lorcet, Vicodin, Anexsia), a schedule III narcotic, and oxycodone (eg, Roxicet, Percodan, Tylox), a schedule II substance, usually provide additional pain relief. Codeine-containing products (schedule III drugs) are not as reliable for alleviating pain. Although the relative potency for oxycodone and hydrocodone is approximately 0.33 (compared with parenteral morphine), that for oral codeine is 0.05. Mixed agonist-antagonist oral agents, such as butorphanol, nalbuphine, and pentazocine, offer no real advantages to opioid agents; yet, they cause a higher incidence of adverse effects. Common side effects include constipation, nausea, respiratory depression, sedation, and urinary retention.
Generally, the approved dosage of hydrocodone is 5-10 mg, combined with 500-750 mg of acetaminophen and taken PO every 6 hours as needed (q6h prn). Oxycodone analgesic preparations typically combine 2.5-5 mg of oxycodone with 325 mg of acetaminophen. They are dosed as 1-2 tablets PO q4h prn for moderate to severe pain. Acetaminophen with codeine (Tylenol #3) contains 30 mg of codeine with 325 mg of acetaminophen. Usually, 1-2 pills q4h prn is recommended.
Elixirs containing hydrocodone (Hycodan) are convenient for children older than 6 years who have moderate to severe pain and who are unable to swallow pills. One teaspoon (5 mL) of Hycodan contains 5 mg of hydrocodone; the dose usually is 1.25-2.5 mg q4h, depending on the child's size and the severity of pain. The elixir of Tylenol with codeine for children contains 120 mg of acetaminophen and 12 mg/5 mL of codeine in an alcohol base (7%).
Generally, orally administered drugs impart a slower onset of action. For patients in severe pain or for those patients who must take nothing by mouth (NPO), parenteral agents may be necessary. Although the intramuscular (IM) route may be more convenient for the staff, the intravenous (IV) route offers a number of advantages. Narcotics given IV provide a rapid and predictable onset of action and are easier to titrate. Morphine and meperidine are the most commonly used parenteral narcotic agents.
A drug combination indicated for the relief of moderate to severe pain.
1-2 tab or cap PO q4-6h prn
<12 years: 10-15 mg/kg/dose acetaminophen PO q4-6h prn; not to exceed 2.6 g/d of acetaminophen
>12 years: 750 mg acetaminophen PO q4h
Single dose not to exceed 10 mg of hydrocodone bitartrate; do not exceed 5 doses in 24 h
Phenothiazines may decrease its analgesic effects; conversely, the toxicity increases when administered concurrently with CNS depressants or tricyclic antidepressants
Documented hypersensitivity to acetaminophen or hydrocodone bitartrate; patients with elevated intracranial pressure
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Tablets contain metabisulfite, which may cause allergic reactions; administer with caution in patients dependent on opiates since this substitution may result in acute opiate withdrawal symptoms; exercise caution when patients have severe renal or hepatic dysfunction; use with caution in elderly persons
Drug combination indicated for the relief of moderate to severe pain.
1-2 tab or cap PO q4-6h prn
0.05-0.15 mg/kg/dose oxycodone PO; not to exceed 5 mg/dose of oxycodone q4-6h prn
Phenothiazines may decrease the analgesic effects of this medication; conversely, its toxicity increases when administered concurrently with either CNS depressants or tricyclic antidepressants
Documented hypersensitivity
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Duration of action may increase in elderly persons; be aware of the patient's total daily dose of acetaminophen; maximum dose of acetaminophen is 4000 mg/d, higher doses may cause liver toxicity
A drug combination indicated for the treatment of mild to moderate pain.
30-60 mg/dose PO (based on codeine content) q4-6h or 1-2 tab q4h; not to exceed 12 tab/24h
0.5-1 mg/kg/dose PO (based on codeine content) and 10-15 mg/kg/dose PO q4h (based on acetaminophen content); not to exceed 2.6 g/24h
Toxicity increases when administered concurrently with CNS depressants or tricyclic antidepressants
Documented hypersensitivity to acetaminophen or codeine phosphate
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Administer with caution in patients dependent on opiates since this substitution may result in acute opiate withdrawal symptoms; exercise caution when patients have severe renal or hepatic dysfunction
Contusions, in particular quadriceps contusions, should be observed closely after injury until the hemorrhage has stopped, which usually occurs 24-48 hours after the injury. It is important to consider compartment syndrome or muscle rupture if the pain or girth of the affected area has not stabilized by 48 hours postinjury.
Myositis ossificans occurs in 9% of all contusions, 4% of mild contusions, 13% of moderate contusions, and 18% of severe contusions. Development of myositis ossificans is a multifactorial problem. Reinjury is a significant factor in prolonging disability.
Rhabdomyolysis must be considered if the contusions are extensive or multiple.
The most serious complication is compartment syndrome. Pain out of proportion to the injury or increasing pain over time are red flags that should alert and prompt the physician to measure the compartment pressures.
The use of protective equipment has helped reduce the incidence of contusions, and the athlete must be instructed on the proper use of protective equipment.
Some data indicate Indocin can help in decreasing heterotopic bone formation. To date, the data are inconclusive, but Indocin may be considered when selecting a medication with which to treat a patient.
For most muscle contusions, the prognosis is excellent. Jackson and Feagin's research on thigh contusions found the average disability time was 13 days for mild contusions, 19 days for moderate contusions, and 21 days for severe contusions.4
Risk factors for a more unfavorable prognosis include injuries that occur during football, previous contusion in the same muscle, delay in treatment for more than 3 days, and large muscle involvement. Reinjury is a significant factor in prolonging disability.
Education about the proper use of protective equipment and aggressive early treatment of contusions is essential.
Best TM. Soft-tissue injuries and muscle tears. Clin Sports Med. Jul 1997;16(3):419-34. [Medline].
Kasemkijwattana C, Menetrey J, Somogyl G, et al. Development of approaches to improve the healing following muscle contusion. Cell Transplant. Nov-Dec 1998;7(6):585-98. [Medline].
Nozaki M, Li Y, Zhu J, et al. Improved muscle healing after contusion injury by the inhibitory effect of suramin on myostatin, a negative regulator of muscle growth. Am J Sports Med. Dec 2008;36(12):2354-62. [Medline].
Jackson DW, Feagin JA. Quadriceps contusions in young athletes. Relation of severity of injury to treatment and prognosis. J Bone Joint Surg Am. Jan 1973;55(1):95-105. [Medline]. [Full Text].
Rothwell AG. Quadriceps hematoma. A prospective clinical study. Clin Orthop Relat Res. Nov-Dec 1982;171:97-103. [Medline].
Ryan JB, Wheeler JH, Hopkinson WJ, Arciero RA, Kolakowski KR. Quadriceps contusions. West Point update. Am J Sports Med. May-Jun 1991;19(3):299-304. [Medline].
Cohen SB, Towers JD, Bradley JP. Rotator cuff contusions of the shoulder in professional football players: epidemiology and magnetic resonance imaging findings. Am J Sports Med. Mar 2007;35(3):442-7. [Medline].
Farges MC, Balcerzak D, Fisher BD, et al. Increased muscle proteolysis after local trauma mainly reflects macrophage-associated lysosomal proteolysis. Am J Physiol Endocrinol Metab. Feb 2002;282(2):E326-35. [Medline]. [Full Text].
MacAuley D. Do textbooks agree on their advice on ice?. Clin J Sport Med. Apr 2001;11(2):67-72. [Medline].
Deal DN, Tipton J, Rosencrance E, Curl WW, Smith TL. Ice reduces edema. A study of microvascular permeability in rats. J Bone Joint Surg Am. Sep 2002;84-A(9):1573-8. [Medline].
Hubbard TJ, Denegar CR. Does cryotherapy improve outcomes with soft tissue injury?. J Athl Train. Sep 2004;39(3):278-9. [Medline]. [Full Text].
Schwartz AJ, Ricci LR. How accurately can bruises be aged in abused children? Literature review and synthesis. Pediatrics. Feb 1996;97(2):254-7. [Medline].
Kneeland JP. MR imaging of muscle and tendon injury. Eur J Radiol. Nov 1997;25(3):198-208. [Medline].
Kneeland JB. MR imaging of sports injuries of the hip. Magn Reson Imaging Clin N Am. Feb 1999;7(1):105-15, viii. [Medline].
Bencardino JT, Rosenberg ZS, Brown RR, et al. Traumatic musculotendinous injuries of the knee: diagnosis with MR imaging. Radiographics. Oct 2000;20 Spec No:S103-20. [Medline]. [Full Text].
Wilkin LD, Merrick MA, Kirby TE, Devor ST. Influence of therapeutic ultrasound on skeletal muscle regeneration following blunt contusion. Int J Sports Med. Jan 2004;25(1):73-7. [Medline].
Rantanen J, Thorsson O, Wollmer P, Hurme T, Kalimo H. Effects of therapeutic ultrasound on the regeneration of skeletal myofibers after experimental muscle injury. Am J Sports Med. Jan-Feb 1999;27(1):54-9. [Medline].
Beiner JM, Jokl P, Cholewicki J, Panjabi MM. The effect of anabolic steroids and corticosteroids on healing of muscle contusion injury. Am J Sports Med. Jan-Feb 1999;27(1):2-9. [Medline].
Mishra DK, Friden J, Schmitz MC, Lieber RL. Anti-inflammatory medication after muscle injury. A treatment resulting in short-term improvement but subsequent loss of muscle function. J Bone Joint Surg Am. Oct 1995;77(10):1510-9. [Medline]. [Full Text].
Powell JW, Barber-Foss KD. Injury patterns in selected high school sports: a review of the 1995-1997 seasons. J Athl Train. Jul 1999;34(3):277-84. [Medline]. [Full Text].
Punwar S, Hall-Craggs M, Haddad FS. Bone bruises: definition, classification and significance. Br J Hosp Med (Lond). Mar 2007;68(3):148-51. [Medline].
Rahusen FT, Weinhold PS, Almekinders LC. Nonsteroidal anti-inflammatory drugs and acetaminophen in the treatment of an acute muscle injury. Am J Sports Med. Dec 2004;32(8):1856-9. [Medline].
Sun JH, Wang YY, Zhang L, et al. Time-dependent expression of skeletal muscle troponin I mRNA in the contused skeletal muscle of rats: a possible marker for wound age estimation. Int J Legal Med. Jan 28 2009;epub ahead of print. [Medline].
Thorsson O, Rantanen J, Hurme T, Kalimo H. Effects of nonsteroidal antiinflammatory medication on satellite cell proliferation during muscle regeneration. Am J Sports Med. Mar-Apr 1998;26(2):172-6. [Medline].
Wankhede AG. The bruise which depicted the pattern of subjacent bone. Forensic Sci Int. Apr 15 2009;186(1-3):e5-7. [Medline].
contusions, bruises, bruising, muscle contusions, hematomas, soft-tissue injuries, ecchymosis, myositis ossificans, heterotopic ossification, compartment syndrome
Michael A Herbenick, MD, Assistant Professor of Orthopedic Surgery and Sports Medicine, Wright State University School of Medicine; Consulting Surgeon, Department of Orthopedic Surgery, Miami Valley Hospital
Michael A Herbenick, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Orthopaedic Surgeons, American Orthopaedic Association, and American Orthopaedic Society for Sports Medicine
Disclosure: Nothing to disclose.
Michael S Omori, MD, Attending Staff, Emergency Medicine Residency, St Vincent Mercy Medical Center; Acting Director, Pediatric Emergency Center, Mercy Children's Hospital; Clinical Assistant Professor, Department of Surgery, University of Toledo Medical Center, The University of Toledo College of Medicine
Michael S Omori, MD is a member of the following medical societies: American College of Emergency Physicians
Disclosure: Nothing to disclose.
Paul Fenton, MD, Assistant Professor, Department of Orthopaedic Surgery, Division of Sports Medicine, Medical College of Ohio at Toledo
Paul Fenton, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Orthopaedic Surgeons, and American Medical Association
Disclosure: Nothing to disclose.
Joseph P Garry, MD, FACSM, FAAFP,, Director of Sports Medicine and Sports Medicine Fellowship, Associate Professor of Family Medicine and Exercise and Sport Science, Department of Family Medicine, East Carolina University Brody School of Medicine
Joseph P Garry, MD, FACSM, FAAFP, is a member of the following medical societies: American Academy of Family Physicians, American College of Sports Medicine, American Heart Association, American Medical Society for Sports Medicine, and North American Primary Care Research Group
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.
Jon B Whitehurst, MD, Clinical Instructor of Surgery, University of Illinois College of Medicine; Partner and Executive Board Member, Rockford Orthopedic Associates; Orthopedic Chairman, Rockford Memorial Hospital
Jon B Whitehurst, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American Orthopaedic Society for Sports Medicine, and Arthroscopy Association of North America
Disclosure: Nothing to disclose.
Sherwin SW Ho, MD, Associate Professor, Department of Surgery, Section of Orthopedic Surgery and Rehabilitation Medicine, University of Chicago
Sherwin SW Ho, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American Orthopaedic Society for Sports Medicine, and Arthroscopy Association of North America
Disclosure: Nothing to disclose.
The authors and editors of eMedicine gratefully acknowledge the contributions of previous author, Brett J Earl, MD, to the development and writing of this article.
Further ReadingRelated eMedicine Topics
Clinical Trials
© 1994-
by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)